What is Beam Therapeutics's return on equity?

Beam Therapeutics (BEAM) reported return on equity of -47.1% in Q3 2025.

What is the long-term trend for Beam Therapeutics's return on equity?

Over 2 years (2021 to 2024), Beam Therapeutics's return on equity has grown at a -20.3% compound annual growth rate (CAGR), from -69.1% to -43.9%.

What does return on equity mean?

Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.

Beam Therapeutics BEAM Return on equity

Return on equity at other companies

Vertex PharmaceuticalsVRTX

24.2%—

Arrowhead ResearchARWR

-46.4%+341pp

CRISPR TherapeuticsCRSP

-31.2%+43.7pp

Cogent Biosciences, Inc.COGT

-85.7%+1.7pp

Protagonist TherapeuticsPTGX

-17.1%-26.1pp

BiogenBIIB

8%-1.2pp

Other financials

Income statement

See full

Revenue$31.7M+325%

Operating income-$107.2M+10.1%

Net income-$94.3M+12.9%

EPS (diluted)-$0.91+26.0%

Balance sheet

See full

Cash & equivalents$288.3M-45.4%

Total debt$250.8M+58.6%

Total equity$1.2B+3.1%

Total assets$1.5B+0.9%

Cash flow

See full

Operating cash flow-$128.5M-23.7%

CapEx$2.2M-27.2%

Free cash flow-$130.7M-22.2%

Valuation

See full

Market cap$3.51B+24.5%

Enterprise value$3.47B+51.2%

P/S21.4×-23.0×

Profitability

See full

Operating margin-226.6%-90.5pp

Net margin-742.7%—

FCF margin-234%-86.6pp

Returns & leverage

See full

Debt / equity0.2×+0.1×

Current ratio17×+8.2×

Where this comes from

Calculated from Beam Therapeutics’s reported figures.

net income/total stockholders equity=-47.1%

Based on trailing twelve months.

The official record: Beam Therapeutics’s 10-Q, filed November 4, 2025, on SEC EDGAR. View the filing →

Ask your AI about Beam Therapeutics's return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Beam Therapeutics's return on equity?: Beam Therapeutics (BEAM) reported return on equity of -47.1% in Q3 2025.
What is the long-term trend for Beam Therapeutics's return on equity?: Over 2 years (2021 to 2024), Beam Therapeutics's return on equity has grown at a -20.3% compound annual growth rate (CAGR), from -69.1% to -43.9%.
What does return on equity mean?: Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.